Advanced Filters
noise
Found 890 clinical trials

SGLT2 Inhibition for Cardiovascular Endpoint Reduction in Hypertension

Hypertension (HTN) is a leading cause of cardiovascular disease (CVD). Despite existing therapies, patients with HTN still face substantial risks, due to pre-existing and ongoing end-organ damage due, in part, to inadequate blood pressure (BP) control. SGLT2 inhibitors (SGLT2i) are recommended for both type-2 diabetes and heart failure to reduce …

60 years of age All Phase 3
J João Presume, MD

Cardiovascular Outcomes Registry in Cardiogenic SHOCK (COR-SHOCK)

The goal of this observational study is to evaluate the clinical outcomes and management approaches of cardiogenic shock throughout the years in adult patients admitted to a Cardiology Department. The main questions it aims to answer are: How have management strategies and clinical outcomes for cardiogenic shock evolved over time? …

18 years of age All Phase N/A
J Johan Sundström

Uppsala Self-Screening of Cardiovascular Health (U-SCREEN)

U-SCREEN is a randomized controlled trial evaluating whether systematic home-based multimodal screening for cardiovascular risk conditions, offered to residents in Region Uppsala turning 50, 55, 60, 65, 70 or 75 years of age, can identify clinically actionable cardiovascular risk factors more effectively than usual care. Participants randomized to the screening …

50 - 75 years of age All Phase N/A

Study of the Progression of Chronic Cardiovascular Conditions

This study will collect physiologic data in patients with cardiovascular conditions and observe the natural history of those conditions for research purposes.

18 years of age All Phase N/A

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.

50 years of age All Phase 3
S Sungha Park, M.D.

Deep Learning of Retinal Photographs and Atherosclerotic Cardiovascular Disease

The research team has developed a deep learning algorithm that predicts anthropometric factors from fundus photographs and an algorithm that predicts cardiovascular disease risk. Fundus photographs are taken for various cardiovascular diseases (myocardial infarction, heart failure, hypertension with target organ damage, high-risk dyslipidemia, diabetic patients, and low-risk hypertension patients), and …

20 - 79 years of age All Phase N/A
R Raymond J Kim, MD

Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis

The primary objective of this study was to determine the ability of cardiac magnetic resonance (CMR) to identify cardiac involvement in patients with sarcoidosis. Patients were to undergo CMR in addition to routine clinical evaluation.

18 years of age All Phase N/A
P Peng SHEN, MPH

Cardiovascular Risk Assessment and Dynamic Monitoring-based Prevention Trial

The CRITICALLY study is a cluster randomized trial that will evaluate the effectiveness of a risk-based dynamic monitoring strategy for the primary prevention of cardiovascular high-risk Chinese adults.

40 - 79 years of age All Phase N/A
A Axel Bauer, Univ.-Prof. Dr.

"Multifactorial Risk Stratification in Acute and Chronic Cardiovascular Disease"

The aim of this study is to develop risk prediction models for the early detection of high-risk patients with structural, rhythmological or inflammatory cardiovascular diseases.

18 years of age All Phase N/A

Molecular and Imaging Studies of Cardiovascular Health and Disease

Biobank is a program which collects biological samples, health information and imaging data from consented patients and stored them at the core facility. These information would be used to study the molecular, imaging and outcome studies of cardiovascular health and disease.

16 - 90 years of age All Phase N/A

Simplify language using AI